Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Colorectal Cancer or Pancreatic Cancer

NCT02973672 is registered in ClinicalTrials.gov with Surgimab as lead sponsor.

NCT NCT02973672
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02973672 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-labeled Anti-carcino-embryonic Antigen Monoclonal Antibody for the Detection of Neoplastic Lesions in Patients With Colorectal Cancer or Pancreatic Cancer
Lead sponsor
Surgimab
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2016
Completion date
May 31, 2019
Enrollment
75 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, metastatic colorectal cancer, pancreas cancer, rectum cancer, recurrent colorectal carcinoma